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PB 2151 | Heparin Calibrated Anti-Xa Assays 
for the Measurement of Low Levels of Direct 
Factor Xa Inhibitors
L. Sabor1, M. Raphaël2, J.-M. Dogné2, F. Mullier2, J. Douxfils2
1CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université 
Catholique de Louvain, Hematology Laboratory, Yvoir, Belgium, 2University of 
Namur, Namur Thrombosis and Hemostasis Center (NTHC), Department of 
Pharmacy, Namur, Belgium
Background: Apixaban, edoxaban and rivaroxaban do not require fre-
quent monitoring but an assessment of the intensity of anticoagula-
tion may be required in emergent or elective surgery. Some experts 
reported that anti-Xa activity below 0.1 IU/mL using heparin cali-
brated chromogenic assays may assert the absence of clinically rele-
vant (i.e. < 30 or < 50 ng/mL depending on the clinical situation) direct 
factor Xa levels. However, it is not clear if difference in response will 
depend on the anti-Xa agent and also on the chromogenic anti-Xa kit 
used to assess the anti-Xa activity.
Aims: To assess if a cut-off of 0.1 UI anti-Xa/mL is able to exclude 
apixaban, rivaroxaban or edoxaban concentration < 30 ng/mL or < 
50 ng/mL using different heparin calibrated chromogenic anti-Xa kits.
Methods: Apixaban, edoxaban and rivaroxaban were added to normal 
pooled plasma at increasing concentrations ranging from 0 to 500 ng/
mL. Anti-Xa activities were measured using 
(1) STA®-Liquid Anti-Xa (STA®LAX) on a STA-R Evolution 
Coagulometer, 
(2) Biophen®Heparin LRT (BP®LRT) on a STA-R Evolution coagulom-
eter and 
(3) HemosIL®-Liquid Anti-Xa (IL®LAX) on a ACL-TOP 700 according 
to manufacturer recommendations.
Results: At 30 ng/mL of rivaroxaban, BP®LRT, STA®LAX and IL®LAX 
provided anti-Xa results >0.1 IU/mL. At 30 ng/mL of apixaban or 
edoxaban, BP®LRT and IL®LAX were below the cut-off but the 
STA®LAX was not. At a concentration of 50 ng/mL, only edoxaban 
with the BP®LRT kit showed an anti-Xa activity < 0.1 UI/mL. 
Conclusions: Low (< 0.1 IU/mL) anti-Xa activity is not safe to exclude 
clinically relevant direct factor Xa levels and should be avoided. It can 
only inform if the drug is present or not. Chromogenic anti-Xa assays 
calibrated against the appropriate agent and using the appropriate 
procedure remains the more accurate method to assess accurately 
low levels of direct FXa inhibitors. 
PB 2152 | Efficacy of a Novel Contact Pathway 
Inhibitor, Ir-CPI, on in vitro Clotting Induced by 
PCI Catheter Segment
J. Douxfils1, D. Gheldof1, S. Derochette2, J. Tassignon2, 
C. Meinguet2, M. Guyaux2, J.-M. Dogné1, E. Godfroid2
1University of Namur, Pharmacy, Namur, Belgium, 2Bioxodes, Marche-en-Famenne, 
Belgium
Background: Ir-CPI, a protein derived from the tick Ixodes ricinus sali-
vary, is a serine protease inhibitor of both factor XIa (FXIa) and FXIIa. 
In patients undergoing percutaneous coronary intervention (PCI), cath-
eter thrombosis may occur as catheters trigger activation of FXII/FXI.
Aims: The aim of this study was to evaluate the effect of Ir-CPI on in 
vitro clotting induced by PCI catheter segment.
Methods: Catheter segments were pressed flat, shaped into rings 
and placed around the perimeter of wells (96-well plate), leaving the 
center of the well unobstructed. To the wells were added serial dilu-
tion of Ir-CPI (until 10 μM) with normal pooled plasma (NPP) or plas-
mas deficient in FXI or FXII. After incubation at 37°C and addition of a 
CaCl2 solution, clot formation was assessed by monitoring absorbance 
at 340nm. Time to reach one-half maximal absorbance (IC50) was de-
fined as the clotting time. Thrombin generation test (TGT) was also 
assessed using catheter segment as trigger of the process. Positive 
inhibitory controls were used (fondaparinux, enoxaparin).
Results: Presence of the catheter reduced the clotting time of NPP; 
an effect reversed by the addition of Ir-CPI. At high concentrations 
(≥ 5μM), Ir-CPI allowed to overpass the clotting time without cath-
eter. On TGT (Fig 1), catheter segments decreased lag time and time 
T A B L E  1 Anti-Xa activities using STA®LAX on a STA-R Evolution 
Coagulometer, BP®LRT on a STA-R Evolution coagulometer and (3) 
IL®LAX on a ACL-TOP 700
concentra-
tion (ng/mL) anticoagulant
STA®LAX 
(UI/mL)
BP®LRT
(UI/mL)
IL®LAX(UI/
mL)
30 Rivavoxaban 0,19 0,12 0,08
30 Apixaban 0,09 0,03 0,04
30 Endoxaban 0,07 0,02 0,02
50 Rivavoxaban 0,45 0,34 0,16
50 Apixaban 0,17 0,10 0,07
50 Endoxaban 0,13 0,06 0,04
F I G U R E  1 Effect of Ir-CPI on Thrombin Generation Time (TGT) in 
NPP exposed to PCI catheter segments
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to peak while the endogenous thrombin potential (ETP) and the peak 
were increased. The presence of Ir-CPI allowed the restoration of 
baseline value, i.e. value of the NPP without exposition to catheter 
segments, in a concentration-dependent manner. 
When clotting was triggered with FXII deficient plasma, we confirmed 
that catheter thrombosis is linked to FXI activation and that clotting 
can be abrogated with 3μM of Ir-CPI.
Conclusions: Ir-CPI can be used to inhibit the clotting induced by cath-
eter segments and achieve antithrombotic effect. Ir-CPI is a promising 
agent with a better safety profile than heparins to face the problem of 
catheter thrombosis during PCI procedures. 
PB 2153 | New Parenteral Poly (2-(acrylamide)-2-
methylpropanesulfonic Acid) - Based Anticoagulants 
(NPACs): Efficacy and Safety Studies in Rats
B. Kalaska1, K. Kaminski2, J. Miklosz1, S.-I. Yusa3, K. Nakai3, 
K. Szczubialka2, D. Pawlak1, M. Nowakowska2, A. Mogielnicki1
1Medical University of Bialystok, Department of Pharmacodynamics, Bialystok, 
Poland, 2Jagiellonian University, Faculty of Chemistry, Krakow, Poland, 3University 
of Hyogo, Department of Applied Chemistry, Hyogo, Japan
Background: Unfractionated heparin (UFH) remains an indispensable 
parenteral drug inhibiting blood coagulation. The biologic variability, 
immunogenicity, unpredictable anticoagulation, and narrow therapeu-
tic range limit its utility. Other parenteral anticoagulants lack of an 
efficient antidote. We recently presented a novel agent neutralizing 
all parental anticoagulants (Trans Res 2016). There is still a need for 
synthetic UFH alternative with the available safe antidote and without 
unacceptable adverse effects.
Aims: The aim of the present study was to develop a novel, safe, and 
easily synthesized poly (2-(acrylamide)-2-methylpropanesulfonic acid) 
(PAMPS)-based parenteral anticoagulants.
Methods: We synthesized, purified and characterized 4 novel 
PAMPS-based polymers named by us as new parenteral anticoagu-
lants (NPAC1, NPAC2, NPAC3, and NPAC4) and PAMPS. Then, we 
screened polymers for potential anticoagulant and antiplatelet activity 
using the in vitro assays. Finally, we examined efficacy and safety of 
the most active polymers in male Wistar rats. We assessed aPTT, PT, 
anti-factor Xa activity, calcium concentration, and platelet aggrega-
tion as efficacy endpoints and cardiorespiratory and hematological 
parameters as safety measures.
Results: We found that all synthesized PAMPS-based polymers and 
PAMPS dose-dependently prolonged aPTT and PT and decreased 
platelet aggregation in vitro. The effect of NPAC1 on aPTT and PT was 
the weakest. Thus, we discontinued studying of this polymer. NPAC2 
and NPAC4 significantly increased the anti-fXa activity. In vivo, all 
polymers significantly prolonged aPTT and PT. NPAC4 and PAMPS 
decreased, NPAC3 increased, whereas NPAC2 did not alter platelet 
aggregation. Unlike NPAC2 and NPAC3, NPAC4 and PAMPS caused 
unacceptable cardiorespiratory and/or hematological complications in 
rats (Table 1).
Conclusions: Documented efficacy and safety of NPAC2 in rats 
makes this polymer a promising candidate for a novel parenteral 
anticoagulant. 
Funding: National Science Centre, 2016/21/B/ST5/00837.
PB 2154 | INR Might Be a Useful Predictor for 
Upcoming Minor to Major Bleedings in Patients 
Treated with NOAC
P. Bhardwaj, L.B. Petersen, T.S. Binko, T.B.S. Jørgensen, 
M.L. Nepper, A.M.K. Andersen, J.R. Petersen, G. Gleerup Fornitz
Amager Hospital, Copenhagen University Hospital, Research Centre of Cardiology, 
Copenhagen, Denmark
Background: Patients treated with Novel Oral Anticoagulants (NOAC) 
are not required to be monitored laboratory, as no qualitative tests 
or therapeutic intervals are recommended today. Despite favorable 
pharmacokinetic properties, bleeding events are some of the few 
complications to the treatment. As there are no recommended global 
anticoagulation tests, prediction of these complications is today not 
possible.
T A B L E  1   In vivo efficacy and safety of new parenteral anticoagulants (NPACs)
 Vehicle NPAC2 NPAC3 NPAC4 PAMPS
aPTT (seconds) 25.7±4.9 94.1±21.9*** 82.9±27.8*** 113.3±24.8*** 109.9±23.4***
PT (seconds) 10.8±0.5 13.5±0.9*** 12.6±1.0*** 114.5±1.2*** 14.6±1.5***
Platelet aggregation - maximal extension (Ω) 12 (8.5-13) 11 (5.5-13.5) 14 (13-19)** 4 (2.5-6)** 4 (0.5-6.5)**
Platelet aggregation - slope 6 (4.5-7) 6 (3-8) 8 (6-10)* 3 (2-4)*** 3 (2-4.5)**
Platelet aggregation - lag time (seconds) 72 (64-89) 71 (69-89) 67 (35-74) 119 (74-196)** 106 (79-297)**
Platelet aggregation - area under the curve 39 (26-41) 34 (19-43) 49 (41-63)** 11 (5-20)** 12 (1-19)**
Blood platelets (103/mm3) 666±65 654±68 666±46 562±103* 497±79***
Cardiorespiratory complications - - - Cardiac and 
respiratory arrest
Cardiac and 
respiratory arrest
Results are shown as mean±SD or as median with lower and upper limits.*P<0.05, **P<0.01, ***P<0.001 vs. vehicle, unpaired Student t test or 
Mann-Whitney test, n=6-11.
